Cyclerion Therapeutics
CYCN
50 hedge funds and large institutions have $25.6M invested in Cyclerion Therapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 17 reducing their positions, and 9 closing their positions.
19,900% more call options, than puts
Call options by funds: $400K | Put options by funds: $2K
0.08% less ownership
Funds ownership: 2.73% → 2.66% (-0.08%)
11% less funds holding
Funds holding: 56 → 50 (-6)
37% less capital invested
Capital invested by funds: $40.7M → $25.6M (-$15.1M)
41% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 17
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$139K |
| 2 |
TFS
TrustCore Financial Services
Brentwood,
Tennessee
|
+$114K |
| 3 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$99.3K |
| 4 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$30.5K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$29.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$369K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$140K |
| 3 |
Two Sigma Investments
New York
|
-$115K |
| 4 |
Millennium Management
New York
|
-$114K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$112K |
CYCN Hedge Fund Activity: Q1 2022 in Review
50 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q1 2022, worth a combined $25.6M — down 37% from $40.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CYCN and 3 opened new positions — a net loss of 6 holders — while 17 trimmed existing stakes and 10 added.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $139K. The largest seller was Two Sigma Advisers, cutting an estimated $369K.
- 50 institutional investors held Cyclerion Therapeutics (CYCN) as of Q1 2022, down from 56 in Q4 2021.
- Funds reported $25.6M of Cyclerion Therapeutics stock for Q1 2022, down 37% quarter-over-quarter.
- 3 funds opened new Cyclerion Therapeutics positions in Q1 2022 and 9 closed out, a net change of -6 holders.
- The largest Cyclerion Therapeutics buyer in Q1 2022 was Bridgeway Capital Management, an estimated $139K added.
- The largest Cyclerion Therapeutics seller in Q1 2022 was Two Sigma Advisers, an estimated $369K sold.
Based on aggregated 13F filings for Q1 2022.